Thank you This live web event has ended. Thank you for attending. Contributors Kenneth Emancipator (Merck) Kenneth Emancipator, MD, DABP led the Merck team which partnered with Agilent Technologies (Dako) to develop the first FDA-approved companion diagnostic in cancer immunotherapy, the 22C3 PD-L1 immunohistochemistry test, which enabled Keytruda® (pembrolizumab) to become the first immunotherapy to be approved for first-line treatment of non-small cell lung cancer. The PD-L1 test also enabled approval of Keytruda as a third-line treatment for gastric cancer. Dr. Emancipator was one of six members of the Keytruda Team to receive the 2015 PhRMA Research and Hope Award for Biopharmaceutical Industry Research on behalf of Merck. More recently, he received the 2017 Philip Levine Award for Outstanding Research from the American Society for Clinical Pathology (ASCP). Dr. Emancipator received his A.B. degree from Harvard University and his MD from St. Louis University. He completed his medical internship at Westchester County Medical Center and his pathology residency at the State University of New York at Stony Brook. He has held appointments at the US National Institutes of Health, the US Food and Drug Administration, Cornell University, Beth Israel Medical Center, Bayer Healthcare, Siemens Healthcare, and Abbott Molecular prior to joining Merck. He also has held various leadership positions with ASCP, eventually becoming its Treasurer and serving on its Board of Directors. He continues to serve as a reviewer for the American Journal of Clinical Pathology.